Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Goletz

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Virchows Archiv : an International Journal of Pathology|March 20, 2010
Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cellsWei-Ming Lin, Uwe Karsten, Steffen Goletz, et al.
International Journal of Experimental Pathology|November 13, 2010
Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cellsWei-Ming Lin, Uwe Karsten, Steffen Goletz, et al.
Cancer Immunology, Immunotherapy : CII|February 21, 2007
The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvsPeter Ravn, Renate Stahn, Antje Danielczyk, et al.
Biotechnology Progress|May 4, 2019
A novel scale-down mimic of perfusion cell culture using sedimentation in an automated microbioreactor (SAM)Steffen Kreye, Rainer Stahn, Karina Nawrath, et al.
Reproductive Biomedicine Online|January 27, 2020
Fully human glyco-optimized recombinant FSH (follitropin epsilon) - a randomized, comparator-controlled phase II clinical trialGeorg Griesinger, Bruno Dietrich, Lars Stöckl, et al.
New Biotechnology|March 8, 2023
Eliminating OFF-frame clones in randomized gene libraries: An improved split β-lactamase enrichment systemOscar Mejias-Gomez, Andreas V Madsen, Lasse E Pedersen, et al.
Frontiers in Immunology|August 1, 2018
Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated CounterpartsChristoph Goletz, Timo Lischke, Ulf Harnack, et al.
Biotechnology Advances|October 24, 2024
Implications of glycosylation for the development of selected cytokines and their derivatives for medical useGiulia Scapin, Ece Cagdas, Lise Marie Grav, et al.
Cancer Immunology, Immunotherapy : CII|February 18, 2006
PankoMab: a potent new generation anti-tumour MUC1 antibodyAntje Danielczyk, Renate Stahn, Dorian Faulstich, et al.
Human Reproduction (Oxford, England)|June 8, 2017
A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trialsKhalid Abd-Elaziz, Ingrid Duijkers, Lars Stöckl, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Virchows Archiv : an International Journal of Pathology|March 20, 2010
Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cellsWei-Ming Lin, Uwe Karsten, Steffen Goletz, et al.
International Journal of Experimental Pathology|November 13, 2010
Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cellsWei-Ming Lin, Uwe Karsten, Steffen Goletz, et al.
Cancer Immunology, Immunotherapy : CII|February 21, 2007
The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvsPeter Ravn, Renate Stahn, Antje Danielczyk, et al.
Biotechnology Progress|May 4, 2019
A novel scale-down mimic of perfusion cell culture using sedimentation in an automated microbioreactor (SAM)Steffen Kreye, Rainer Stahn, Karina Nawrath, et al.
Reproductive Biomedicine Online|January 27, 2020
Fully human glyco-optimized recombinant FSH (follitropin epsilon) - a randomized, comparator-controlled phase II clinical trialGeorg Griesinger, Bruno Dietrich, Lars Stöckl, et al.
New Biotechnology|March 8, 2023
Eliminating OFF-frame clones in randomized gene libraries: An improved split β-lactamase enrichment systemOscar Mejias-Gomez, Andreas V Madsen, Lasse E Pedersen, et al.
Frontiers in Immunology|August 1, 2018
Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated CounterpartsChristoph Goletz, Timo Lischke, Ulf Harnack, et al.
Biotechnology Advances|October 24, 2024
Implications of glycosylation for the development of selected cytokines and their derivatives for medical useGiulia Scapin, Ece Cagdas, Lise Marie Grav, et al.
Cancer Immunology, Immunotherapy : CII|February 18, 2006
PankoMab: a potent new generation anti-tumour MUC1 antibodyAntje Danielczyk, Renate Stahn, Dorian Faulstich, et al.
Human Reproduction (Oxford, England)|June 8, 2017
A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trialsKhalid Abd-Elaziz, Ingrid Duijkers, Lars Stöckl, et al.
Pageof 6